To evaluate choroidal and choriocapillaris changes in patients with central serous chorioretinopathy, undergone sub threshold micropulse laser treatment, following any improvement with conservative therapy with Acetazolamide and/or Eplerenone
Diagnosis of central serous chorioretinopathy (CSC) with no response to conservative therapy, consisted in Acetazolamide and Eplerenone after six months.
Foveal serous retinal detachment for at least 6 months.
Minimum age of 18 years old at the screening time
Reading and comprehension skills of informed consent
Previous retinal treatment for CSC, except for Acetazolamide and Eplerenone
No diffuse retinal epitheliopathy
Other concomitant ocular diseases, such as age related macular degeneration, diabetic retinopathy, choroidal neovascularization
Not controlled glaucoma with eyedrops, or advanced glaucoma
Patients older than 18 years old, with diagnosis of central serous chorioretinopathy since at least 6 months, undergone Acetazolamide and/or Eplerenone therapy with no improvement after 6 months.
Case-only
Prospective
Subthreshold Micropulse Laser Treatment
Other interventionSubthreshold micropulse laser treatment consists in 33 spots of 100 microns, distance among each spot of 2.50 microns, duration of 200 sec, power of 250 milliwatt (mW) duty cycle 5%.
Vessel density changes
Evaluation of changes in vessel density of choriocapillaris by optical coherence tomography (OCT) angiography before and after treatment
Choroidal thickness
Evaluation of changes in choroidal thickness before and after treatment.
Choroidal thickness and vessel density
Correlation among changes in choroidal thickness and changes in vessel density of choriocapillary with best corrected visual acuity.
Qualitative analysis of retino-choroidal vascularization with identification of vascular pattern
To qualitatively evaluate the vascular patterns using optical coherence tomography (OCT) - angiography and to verify if a particular one is associated with a greater response to subthreshold micropulse laser treatment.
Metamorphopsia
Evaluation of quantitative improvement of metamorphosia by M-CHARTS after treatment.
Click on the lead sponsor to view all of their trials.
